Introduction
Over 30 human papillomavirus (HPV) types infect mucosal surfaces, with types -16, -18, -31, -33, -35, -45, -51, -52 or -56 being positively associated with cervical carcinoma and the precursor tumour, squamous intraepithelial lesions (SIL). Accordingly, infection with these HPVs is believed to confer a high risk of cervical carcinoma (Bavin et al., 1993 ; Cusick et al., 1992 ; de Villiers, 1992 ; zur Hausen, 1994) . Amongst such high-risk HPVs, HPV-16 is usually most frequent and, in our locality, 62 % of cervical cancers contain this HPV (Cavuslu et al., 1997) .
Whilst many women are infected with high-risk HPVs, most infections are clinically inapparent ; a few infections progress to SIL and only a minority result in cervical carcinoma. Cell-mediated immunity (CMI) plays a decisive role in this subjects exhibited a proliferative response ; P l 0n023) and were again most prevalent amongst HPV-16 DNA-positive LSIL (6 of 14, 43 %), as compared with HPV-16 DNA-positive HSIL (5 of 23, 22 %) or HPV-16 DNA-positive cervical cancer patients (1 of 4, 25 %, P 0n05). In contrast, for asymptomatic women, responsiveness was statistically independent of HPV-16 DNA status, i.e. responsiveness in HPV-16 DNA-positive and DNAnegative subjects was observed in 3 of 15 (20 %) and 1 of 5 (20 %) cases, respectively (P 0n05). There were no associations between detection of HPV-16 mRNA and proliferative responses (P 0n05). These data suggest that HPV-16 E5-specific T-helper activity is depressed amongst women with HSIL lesions. equation as high-risk HPV infections and cervical neoplasias are invariably more prevalent amongst those with compromised T-cell function (e.g. iatrogenically immunosuppressed allograft recipients and women infected with human immunodeficiency virus ; Frazer & Tindle, 1992 ; Benton et al., 1992) . Whilst the protective CMI mechanisms involved are unknown, they probably include delayed-type hypersensitivity reactions and\or cytotoxic T-cell responses.
Immunological investigations of high-risk HPVs have concentrated upon the L1, L2, E6 and E7 proteins. Such studies have identified T-cell epitopes and led to successful phase-1 trials of HPV-16\HPV-18 E6\E7 vaccines (Borysiewicz et al., 1996) . However, these HPV proteins may not be the dominant targets for protective CMI responses in infected humans (Luxton et al., 1997) . Here, we have investigated proliferative T-cell reactivity to HPV-16 E5 peptides as : (i) E5 is expressed soon after infection, with both mRNA and protein detectable in low-grade SIL (LSIL) (Stoler et al., 1992 ; Kell et al., 1994 ; Biswas et al., 1997) ; (ii) the prevalence of E5-containing mRNA increases with advancing severity of disease (Biswas et al., 1997) ; (iii) E5 protein is expressed at the cell surface as a result of endosome recycling of ligands and formation of intercellular gap junctions (Goldstein et al., 1985 ; Oelze et al., 1995) ; and (iv) amino acid sequences of E5 proteins are poorly conserved between different HPVs, making them potentially good HPV type-specific targets.
Our a priori hypothesis was that women with HPV-16 infections are likely to exhibit virus-specific CMI to HPV-16 proteins, which, if protective, should be inversely correlated with disease severity. Here, we describe a cross-sectional study to establish whether proliferative responses to HPV-16 E5 are associated with the grade of cervical lesion and HPV-16 nucleic acid status of the lesions. We concentrated upon patients with premalignant lesions since this is likely to be the stage of disease at which an effective CMI response plays a decisive role.
Methods
Clinical specimens. Seventy-five women [20 with no cervical lesions (asymptomatic), 15 with LSIL, 33 with high-grade cervical SIL (HSIL) and 7 with cervical cancer (Ca)] attending colposcopy clinics within the gynaecological outpatient department at St Thomas' Hospital (London, UK) were recruited (Table 1) . We did not attempt to obtain a group of women that had never been exposed to HPV-16. Firstly, because this virus is ubiquitous amongst sexually active women (IARC, 1995) and even sexually inexperienced women may be infected via nonsexual routes (Cason, 1996) . Secondly, our primary goal was not to compare responses between those who were and those who were not exposed to HPV-16, but to determine whether immune responses to HPV-16 E5 occurred and were associated with lesion severity. A cervical brush scrape collected with an Axibrush (Colgate Medical), 16 ml blood (taken into EDTA), and 4 ml clotted blood were obtained from each subject. Approval for the collection of samples was obtained from the Research Ethics Committee of St Thomas' Hospital.
PCR assays for HPV-16 DNA. Cervical brush scrapes were resuspended in 5 ml sterile Dulbecco's PBS and a 1 ml aliquot was treated with Proteinase K (Boehringer Mannheim). Samples were screened for HPV-16 E6 DNA using well-characterized PCRs (primers were nucleotides 94-113 and 562-543 ; PCR sensitivity was 25 copies of HPV-16 DNA) and for E5 DNA (primers were nucleotides 3837-3868 and 4110-4078) in a less-sensitive PCR (sensitivity was 250 copies of HPV-16 ; Cavuslu et al., 1996 ; Mant et al., 1997) . Samples were considered positive for HPV-16 DNA if they were positive in one or both assays. All PCRs were performed under stringent precautions to avoid contamination and, to control for the quality of samples with respect to the possibilities of non-specific PCR inhibitors and\or insufficient quantities of DNA present in clinical samples, PCRs using primers for human β-globin (PC04 and GH20) were performed . As a control against PCR contamination, we analysed nine randomly selected samples (numbers 749, 758, 812, 816, 681, 686, 687, 767 and 781) by restriction fragment polymorphism analyses (RFLP) of E5 amplicons. Four different RFLP patterns were found [687, 681, 758, 749 and 812 had lost the SspI restriction endonuclease (RE) cut site ; 686 and 816 resembled the HPV-16 reference isolate ; sample 781 had lost the XcmI and NspI RE sites ; and sample 767 had lost the SspI, XcmI and NspI RE sites]. These data reveal that a single source (e.g. laboratory) contamination of samples was unlikely.
RT-PCR assay for HPV-16 early region mRNA (EmRNA).
This assay was used to establish whether HPV-16 DNA-positive subjects had replicative infections as evidenced by EmRNA (Biswas et al., 1997) . Each cervical brush scrape (1 ml) in PBS was taken into RNAzol and subjected to reverse transcription primed with a 25-30-mer oligo(dT) primer (Pharmacia Biotechnology) and Moloney murine leukaemia virus reverse transcriptase (Life Technologies) and then a nested PCR (Biswas et al., 1997) . This test has an analytical sensitivity of about 1 000 copies of HPV-16 mRNA. As controls for these assays, RT-PCR for human keratin were performed ; samples were only considered suitable for HPV-16 EmRNA analyses if they were positive for keratin mRNA.
HPV-16 E5 synthetic peptides. Synthetic peptides corresponding to amino acids 1-8, 5-13, 10-18, 15-23, 20-28, 25-33, 30-38, 35-43, 40-48, 45-53, 50-58, 55-63, 60-68, 65-73, 70-78 and 75-83 were constructed by Fmoc chemistry (Cason et al., 1989 ; Kell et al., 1994) . These peptides were based on the predicted amino acid sequence from DNA of the HPV-16 reference isolate (Seedorf et al., 1985 ; Halbert & Galloway, 1988 ).
Short-term T-cell lines.
We utilized a commonly used approach to generate short-term T-cell lines (Shepherd et al., 1996 ; Luxton et al., 1997) . Briefly, 16 ml EDTA-treated blood was layered onto 24 ml FicollPaque (Pharmacia) and centrifuged at 200 g for 20 min at room temperature. Mononuclear cells were harvested and washed three times by resuspension in, and centrifugation through, RPMI-1640 containing 2 mM -glutamine, 1i10& U\l penicillin, 25 g\l streptomycin sulphate and 10 % (v\v) foetal calf serum (RPMI\FCS medium). Cells were resuspended in 10 % (v\v) DMSO in FCS, divided into three aliquots and frozen at k1 mC\min to k70 mC. One aliquot was thawed and adjusted to 1i10) viable (by trypan-blue exclusion) cells\l in RPMI\FCS containing 2i10% U\l recombinant human interleukin-2 (Sigma), 4i10$ U\l recombinant human interleukin-4 (Sigma) and an equimolar mix of 16 (non-conjugated) E5 9-mer peptides (final concentration of pooled peptides was 20 µM in RPMI\FCS) and incubated at 37 mC in a humidified atmosphere containing 5 % (v\v) CO # in air. On day 3, medium was replenished and on day 7, cells were washed, resuspended in fresh RPMI\FCS containing peptides, interleukins (as above) and supplemented with 2i10' viable autologous mitomycin C-treated cells\l (cells were treated with 1 g\l mitomycin C for 3 h at 37 mC, washed twice in PBS, then resuspended in RPMI\FCS) as antigenpresenting cells.
Proliferative T-cell responses. To determine T-cell reactivity to peptides, we used a colorimetric assay which involved the indirect measurement of mitochondrial activity as determined by reduction of a tetrazolium salt (3-[4,5-dimethylthiazol-2-yl]-2,5-diphenyltetrazolium bromide ; MTT). This assay produces results equivalent to [$H]thymidine tests and has been used to determine T-cell interleukin-2 production (Denzoit & Lang, 1986) . On day 14, cells were washed (as above), and 50 µl per well of a suspension containing 1i10) viable cells\l was aliquotted into wells 18-86 of a 96-well flat-bottomed tissue culture plate (Corning). Then, 10 µl per well of pooled 9-mer peptides (as above) was added to wells 12-80 ; three wells contained 10 µl per well of medium alone (i.e. non-stimulated controls) and three contained 10 µl per well Concanavalin A (Con A ; at 12 mg\l in RPMI\FCS). Forty-eight hours later, 50 µl of a solution containing 2 g\l MTT in RPMI\FCS was added to each well for 4 h at 37 mC. Plates were centrifuged at 400 g for 5 min at room temperature, the supernatants were aspirated and 100 µl per well DMSO was added ; colour development was assessed (as A &(! ) after a 10 min incubation at room temperature using a Labsystems plate reader. 
Results (i) Study group characteristics
Only cervical cancer patients were significantly different in age (older) from asymptomatic women (P l 0n03 ; Table 1 ). Two of the 75 samples (both SIL) were negative for β-globin DNA and hence excluded from HPV-16 DNA analyses. HPV-16 DNA was detected in cervical brush samples from 40 of 53 (75 %) patients with cervical disease and 15 of 20 (75 %) asymptomatic women (Fet, P 0n5 ; Table 2 ). Two samples (one asymptomatic and one SIL) were negative for keratin Table 2 . Proliferative T-cell responses amongst subjects with/or without cervical lesions and with differing HPV-16 nucleic acid status
Data are recorded as the number of T-cell responding samples over the total number of samples tested and the percentage positivity in each group is given in parentheses. Subjects are either positive (j) or negative (k) for HPV-16 DNA or EmRNA. 
HPV-16 status

(ii) Proliferative responses to HPV-16 E5 peptides
Proliferative responses to pooled HPV-16 E5 peptides were found for 16 of the 75 (21 %) samples (Table 2 and Fig. 1 ). For 32 samples, there were sufficient cells to assess reproducibility in duplicate, which was invariably high (e.g. subject 750, r# l 0n82 ; Fig. 1 ). There was no difference between the frequencies of T-cell responses for asymptomatic women (4 of 20, 20 %) and those with neoplasia (12 of 55, 22 %) (Fet, P 0n05). Amongst patients, T-cell responses were most common in women with LSIL (6 of 
* A, asymptomatic. † Positive (j) or negative (k) for HPV DNA by PCR. ‡ Results of RT-PCR for EmRNA. § Percentage of cell-lines with a stimulation index (SI) greater than 1n5 ; the number of cell lines that were positive over the number tested is given in parentheses. ¶ The number of cell lines with an SI greater than 2n499.
(5 of 33, 15 %) or cancer (1 of 7, 14 %) ; this trend was significant (M-H χ# test, P l 0n027 ; Table 2 ). Proliferative responses were more common amongst HPV-16 DNA-positive subjects [15 of 56 (27 %) versus 1 of 17 (6 %) for HPV-16 DNA-negative subjects ; Fet, P 0n05 ; Table 2 Five of 16 (31 %) proliferative responsive patients were EmRNA-positive and 9 of 55 (16 %) non-responders were EmRNA-positive (Fet, P 0n05). There were no significant associations between proliferative responses and EmRNA status in any of the subject groups (Fet and M-H χ# tests, all P 0n05 ; Tables 2 and 3 ). Equivalent analyses of responses to ConA failed to produce any differences (all P 0n05 : data not shown).
Discussion
We have demonstrated that proliferative responses to HPV-16 E5 peptides are inversely correlated with the severity of squamous intraepithelial neoplasia lesions (P l 0n03). A similar trend was noted for those patients with HPV-16 DNApositive lesions (P 0n05) and proliferative responses were not detected amongst any HPV-16 DNA-negative patients (P 0n05). Thus, our data are similar to those of Tsukui et al. (1996) who reported an inverse correlation between in vitro CMI responses to the HPV-16 E7 protein and severity of lesion.
Proliferative responses were common amongst asymptomatic women with or without HPV-16 DNA (both 20 % ; P 0n05) and this is in broad agreement with other studies which have reported that 18-47 % of healthy subjects respond to HPV-16 L1 and E7 proteins (Luxton et al., 1997 ; Shepherd et al., 1996) . Cumulatively, these data suggest that exposure to this virus is commonplace, usually resulting in induction of detectable in vitro CMI responses. The high rate (75 %) of HPV-16 PCR positivity reported here for asymptomatic women was unsurprising since the subjects were recruited from a group with a high probability of being infected with HPV-16.
EmRNA status of the subjects was determined as it was anticipated that proliferative responses might be more common amongst those subjects with transcriptionally active infections. Also, the comparative insensitivity of the RT-PCR assay (detection limit of 1 000 EmRNA copies ; Biswas et al., 1997) may make it an indirect measure of a high virus load as compared to the HPV-16 PCRs (E5 sensitivity was 250 DNA copies and E6 was 25 DNA copies ; Mant et al., 1997) . However, whilst there was a significant trend for EmRNA positivity with increasing grade of cervical lesion (P 0n0007), no association between HPV-16 EmRNA status and proliferation was found (P 0n05).
As cells were cultured with E5 peptides prior to assay, our results could reflect in vitro immunization. However, this seems unlikely because of the inverse correlation between disease status and proliferative responses and the positive association of the latter with HPV-16 DNA for those with lesions. It also seems a remote possibility that the proliferative responses detected represented cross-reactivity induced by other HPVs. Indeed, E5 protein sequences are poorly conserved between HPVs and HPV-35, phylogenetically the closest type to HPV-16, only exhibits a 53 % amino acid homology with HPV-16 E5.
Others have reported that decreased Th cell proliferation responses reflect a depression of Th " activity to HPV-16 antigens with increasing grade of neoplasia (Tsukui et al., 1996 ; Coleman et al., 1994 ; Luxton et al., 1997) . In preliminary studies, we found a low frequency of weak seroreactivity to selected E5 peptides, but no HPV-16 E5-specific IgG # α antibodies (data not shown). Cell-culture supernatants from 21 samples were also analysed for interferon-γ production and this was detected in 4 of 8 (50 %) samples from T-cell responders and in 3 of 13 (23 %) non-responsive subjects (data not shown). On the basis of the latter, the proliferative responses we detected may also reflect Th " -like activity. The present data reveal that women with increasingly severe HPV-16-associated lesions have decreasing HPV-16 E5-specific proliferative responses. This suggests that such responses may correlate with protective CMI and hence, disease susceptibility. Thus, longitudinal studies of T-cell responses to HPV-16 E5 amongst HPV-16 DNA-positive patients with low-grade lesions, mapping of HPV-16 E5 Th epitopes, formal characterization of the nature (Th " or Th # ) of these responses to E5 antigens, and the investigation of CMI to other HPV-16 early proteins such as E1, E1-E4 and E2 are now indicated.
